Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene ther...
Summit Therapeutics plc ('Summit', the 'Company', or the 'Group')Director / PDMR Share DealingOxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces ...
Repros Therapeutics will release its earnings data before the market opens on Thursday, March 29th. Analysts expect Repros Therapeutics to post earnings of per share for the quarter.
Will work with Pear Therapeutics on a prescription software range
SAN DIEGO, July 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis Foundation (CF Foundation) Therapeutics, Inc. The completion of these success-driven milestones has triggered an undisclosed payment to Arcturus from the CF Foundation to advance LU...
CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island. The company plans to invest up t...
UK-based therapeutics developer Evox Therapeutics has secured $45.4m in a series B financing round to support new drug development. The...Read More... The post Evox Therapeutics raises new funds to support drug development appeared first on Pharmaceutical Technology.
The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.
The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”
Shares of PTC Therapeutics Inc. (PTCT) have gained as much as 24% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) is up just 8.6% for the same period.
A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis...
Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed a new CEO to lead the company. Pablo Cagnoni enters the position, joining the biotech from Tizona Therapeutics, which he led as CEO. He joins the company not long after its second successful financing round, after the company raised $100 million in March. read more
PTC Therapeutics Inc. (rare disease and cancer therapeutics) netted $102.5mm through the public offering of 4mm shares at $27...
Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan Legault told INN. The post Antibe Therapeutics Looking for More Licensing Deals appeared first on Investing News Network.
Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...
Apricus Biosciences (NASDAQ:APRI) has announced it has signed an agreement to merge with Seelos Therapeutics in an all-stock transaction. As quoted in the press release: The merged company will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with a highly unmet medical need. Upon … Continued The post Apricus...
The various smart phone apps that are being developed to monitor or help manage diseases like diabetes or insomnia are now being referred generally as digital therapeutics (see: Can “Digital Therapeutics” Be as Good as Drugs?). This article provocatively asks the question whether some of these apps can ultimately substitute...
Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license sever...
NewsUnder the terms of the agreement, Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.
RNA therapeutics developer Silence Therapeutics announced on Monday that its chief executive Ali Mortazavi will leave the company with immediate effect after a six year stay. Silence said that unti...
Shares of G1 Therapeutics Inc. (GTHX) have returned an impressive 103% year-to-date while the iShares NASDAQ Biotechnology Index (ETF)(IBB) is up a paltry 2.8% during the same period.
Sigilon Therapeutics Inc. granted Eli Lilly & Co. exclusive global rights to its Afibromer living therapeutics technology for...
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Roche’s subsidiary Genentech has entered into a strategic drug discovery collaboration with Lodo Therapeutics, which is focused on the creation of therapeutics derived from nature that will impact patients across the world.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock Ventures. Cedilla is leveraging a growing understanding of the principles that dictate protein stability and appl...